Neurogenic Bladder: Epidemiology, Diagnosis, and Management.
Panicker JN.
Semin Neurol. 2020 Oct;40(5):569-579. doi: 10.1055/s-0040-1713876. Epub 2020 Oct 16.
Diagnosis and clinical evaluation of neurogenic bladder.
Amarenco G, Sheikh Ismaël S, Chesnel C, Charlanes A, LE Breton F.
Eur J Phys Rehabil Med. 2017 Dec;53(6):975-980. doi: 10.23736/S1973-9087.17.04992-9. Epub 2017 Oct 25.
Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury.
Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, Patel A, Plata M, Del Popolo G.
World J Urol. 2018 Oct;36(10):1517-1527. doi: 10.1007/s00345-018-2301-z. Epub 2018 May 11.
Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin.
Ferreira A, Nascimento D, Cruz CD.
Int J Mol Sci. 2023 Feb 7;24(4):3273. doi: 10.3390/ijms24043273.
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment.
Stein R, Bogaert G, Dogan HS, Hoen L, Kocvara R, Nijman RJM, Quadackers JSLT, Rawashdeh YF, Silay MS, Tekgul S, Radmayr C.
Neurourol Urodyn. 2020 Jan;39(1):45-57. doi: 10.1002/nau.24211. Epub 2019 Nov 13.
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B.
Medicine (Baltimore). 2023 Jul 1;102(S1):e32377. doi: 10.1097/MD.0000000000032377.
Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
Haab F.
Neurourol Urodyn. 2014 Jul;33 Suppl 3:S2-5. doi: 10.1002/nau.22636.
Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F, Nitti V.
Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630.
Pharmacotherapy for Pediatric Neurogenic Bladder.
Kroll P.
Paediatr Drugs. 2017 Oct;19(5):463-478. doi: 10.1007/s40272-017-0249-x.
Editorial Comment to Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder.
Sekido N.
Int J Urol. 2020 Oct;27(10):905. doi: 10.1111/iju.14335. Epub 2020 Aug 7.
